Empower the Immune System to Treat Glioblastoma: DNA as Medicine
Time: 2:15 pm
day: Day One
Details:
- Explore DNA medicines that have the potential to create robust,
antigen-specific T cell responses - Evaluate Inovio’s DNA medicine, INO-5401 has promising, early data in
GBM showing early efficacy, and immunogenicity - Discuss Inovio’s DNA medicine, its technology, and other promising
approaches to GBM therapy will be discussed
Speakers:
Dr. Skolnik oversees all of Inovio’s cancer immunotherapy programs, as well as those for several infectious diseases. Dr. Skolnik was previously at Tetralogic Pharmaceuticals, where he was Vice President of Clinical Research and later Chief Medical Officer, and oversaw all clinical programs in oncology, infectious diseases and dermatology. He was also a Medical Affairs lead…Read more